PPD expands capabilities in early development

Among the additions are significant neuroscience and ethno-bridging expertise
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
WILMINGTON, N.C.—In early December, PPD Inc. expanded its early development research services by adding significant neuroscience and ethno-bridging expertise, broadening its capabilities to provide increased access to patients and special populations at PPD-owned clinical research units (CRUs).
 
To enhance its ability to conduct complex, procedurally intensive Phase 1 and Phase 1b early development clinical research in neurology, PPD has added a 52-bed CRU in Orlando, Fla. The recently acquired unit reportedly has a strong track record of recruiting and conducting early phase trials in multiple neurological indications, such as Alzheimer’s disease. The Orlando CRU has completed more than 50 Phase 1 studies in Alzheimer's and other central nervous system/neurodegenerative therapeutic areas.
 
Additionally, PPD’s Las Vegas CRU—a hospital-adjacent, 24-bed unit specializing in endocrinology and metabolic trials—has expanded its portfolio to include the conduct of Japanese ethno-bridging studies. These studies allow biopharmaceutical companies to incorporate Asian patient data in parallel with western regions to initiate Phase 3 studies in Asian markets sooner.
 
“By tapping into nearby high-concentration Japanese communities, we are able to study the way this population metabolizes medications and recommend alterations in safety, efficacy or dosages,” said Scott Dove, vice president of early development at PPD. “In addition to ethno-bridging, we have expanded our distinct capabilities in neuroscience and other niche therapeutic areas to study patient populations more reflective of the products’ end-users. Increasing client access to special patient populations opens exciting opportunities for the development of important new therapies to address unmet medical needs.”

Related Topics

Published In

Volume 15 - Issue 12 | December 2019

December 2019

December 2019 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Image Alt Text	A laboratorian wearing blue gloves places a PCR sample into a real-time PCR thermocycler, the model shown is blue and white with a large digital screen.
From primer design to sample preparation, explore comprehensive strategies to optimize PCR throughput and reproducibility.
Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue